Clinical Trial

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-11; most recent amendment 2026-02-10.
Status change: Not Yet Recruiting → Recruiting 2025-11-05
Trial Details
NCT Number NCT07182149
Lead Sponsor Normunity AccelCo, Inc.
Conditions HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer +2 more
Enrollment 150 participants
Start Date 2025-10-30
Primary Completion 2027-05-30 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-12